PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

A Study of Avelumab in Combination With Axitinib In Non-Small Cell Lung Cancer (NSCLC) or Urothelial Cancer (Javelin Medley VEGF)

Phase 2

Terminated

Conditions: Urothelial Cancer
Non-Small Cell Lung Cancer

Interventions: Drug: Avelumab (MSB0010718C)
Drug: Axitinib (AG-013736)

First Posted Date: 2018-03-21

Last Posted Date: 2024-04-09

Lead Sponsor: Pfizer

Target Recruit Count: 61

Registration Number: NCT03472560

Locations: 🇨🇳
National Cheng Kung University Hospital, Tainan, Taiwan
🇰🇷
National Cancer Center, Goyang-si, Gyeonggi-do, Korea, Republic of
🇨🇳
Chi Mei Hospital, Liouying, Tainan City, Liouying District, Taiwan

and more 31 locations

Safety, Tolerability And Efficacy Study Of Topical PF-06763809 In Subjects With Mild To Moderate Chronic Plaque Psoriasis

Phase 1

Completed

Conditions: Psoriasis

Interventions: Drug: PF-06763809
Other: Vehicle
Drug: Calcipotriene/calcipotriol
Drug: Betamethasone

First Posted Date: 2018-03-19

Last Posted Date: 2020-06-25

Lead Sponsor: Pfizer

Target Recruit Count: 18

Registration Number: NCT03469336

Locations: 🇩🇪
bioskin GmbH, Hamburg, Germany
🇩🇪
Rothaar Studien GmbH, Berlin, Germany

Trial in Adult Subjects With Acute Migraines

Phase 3

Completed

Conditions: Migraine, With or Without Aura

Interventions: Drug: Placebo
Drug: Rimegepant

First Posted Date: 2018-03-12

Last Posted Date: 2023-02-16

Lead Sponsor: Pfizer

Target Recruit Count: 1811

Registration Number: NCT03461757

Locations: 🇺🇸
Tidewater Integrated Medical Research, Virginia Beach, Virginia, United States
🇺🇸
Sundance Clinical Research, Saint Louis, Missouri, United States
🇺🇸
Ki Health Partners LLC DBA New England Institute for Clinical Research, Stamford, Connecticut, United States

and more 60 locations

Mevrometostat Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma

Phase 1

Recruiting

Conditions: Follicular Lymphoma (FL)
Small Cell Lung Cancer (SCLC)
Metastatic Castration Resistant Prostate Cancer (mCRPC)

Interventions: Drug: Mervometostat (PF-06821497)
Drug: Enzalutamide

First Posted Date: 2018-03-09

Last Posted Date: 2024-11-01

Lead Sponsor: Pfizer

Target Recruit Count: 343

Registration Number: NCT03460977

Locations: 🇺🇸
Urological Associates of Southern Arizona, P.C ., Tucson, Arizona, United States
🇺🇸
Banner-University Medical Center Tucson, Tucson, Arizona, United States
🇺🇸
The University of Arizona Cancer Center-North Campus, Tucson, Arizona, United States

and more 96 locations

A Study to Evaluate PF-06730512 in Adults With Focal Segmental Glomerulosclerosis (FSGS)

Phase 2

Terminated

Conditions: Focal Segmental Glomerulosclerosis (FSGS)

Interventions: Drug: PF-06730512

First Posted Date: 2018-02-28

Last Posted Date: 2024-04-18

Lead Sponsor: Pfizer

Target Recruit Count: 47

Registration Number: NCT03448692

Locations: 🇺🇸
The Cleveland Clinic - Investigational Drug Pharmacy, Cleveland, Ohio, United States
🇺🇸
The Cleveland Clinic, Cleveland, Ohio, United States
🇺🇸
The Kirklin Clinic of University Alabama Birmingham Hospital, Birmingham, Alabama, United States

and more 104 locations

Single-dose Study of [14C]PF-05221304 Metabolism and Excretion in Healthy Adult Male Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: [14C]PF-05221304

First Posted Date: 2018-02-27

Last Posted Date: 2018-12-04

Lead Sponsor: Pfizer

Target Recruit Count: 6

Registration Number: NCT03448172

Locations: 🇺🇸
Covance Clinical Research Unit Inc., Madison, Wisconsin, United States

Post Marketing Surveillance Study to Observe Safety and Efficacy of IBRANCE®

Recruiting

Conditions: Breast Neoplasm

First Posted Date: 2018-02-26

Last Posted Date: 2024-08-28

Lead Sponsor: Pfizer

Target Recruit Count: 540

Registration Number: NCT03445637

Locations: 🇰🇷
Pfizer Tower, Seoul, Korea, Republic of

Apixaban Drug Utilization Study In Stroke Prevention In Atrial Fibrillation (Spaf)

Completed

Conditions: Atrial Fibrillation

Interventions: Drug: VKA
Drug: apixaban
Drug: rivaroxaban
Drug: dabigatran

First Posted Date: 2018-02-22

Last Posted Date: 2023-06-09

Lead Sponsor: Pfizer

Target Recruit Count: 51690

Registration Number: NCT03441633

Locations: 🇪🇸
IDIAP Jordi Gol, Barcelona, Cataluña, Spain

A Study of ARRY-371797 (PF-07265803) in Patients With Symptomatic Dilated Cardiomyopathy Due to a Lamin A/C Gene Mutation

Phase 3

Terminated

Conditions: Dilated Cardiomyopathy
Lamin A/C Gene Mutation

Interventions: Drug: ARRY-371797 (PF-07265803)
Other: Placebo

First Posted Date: 2018-02-20

Last Posted Date: 2024-01-09

Lead Sponsor: Pfizer

Target Recruit Count: 77

Registration Number: NCT03439514

Locations: 🇺🇸
University of Washington Medical Center, Seattle, Washington, United States
🇳🇴
Oslo University Hospital, Rikshospitalet, Oslo, Norway
🇺🇸
Emory University Hospital, Atlanta, Georgia, United States

and more 100 locations

Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis

Phase 3

Active, not recruiting

Conditions: Dermatitis, Atopic

Interventions: Drug: Abrocitinib 200 mg
Drug: Placebo
Drug: Abrocitinib 100 mg

First Posted Date: 2018-02-06

Last Posted Date: 2024-10-23

Lead Sponsor: Pfizer

Target Recruit Count: 3162

Registration Number: NCT03422822

Locations: 🇨🇦
University of British Columbia Department of Dermatology and Skin Science, Vancouver, British Columbia, Canada
🇨🇦
The Centre for Clinical Trials, Oakville, Ontario, Canada
🇨🇦
AvantDerm, Toronto, Ontario, Canada

and more 538 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy